SUMMARY
For most viruses, including HIV, there is a need for antimicrobials that target unique viral molecular properties. Acyclovir (ACV) is such a drug for human herpesviruses (HHVs): it is activated into a HHV-DNA polymerase inhibitor exclusively by HHV-kinases and thus does not suppress other viruses. Here, we report on the direct inhibition of HIV-1 reverse transcriptase (RT) by phosphorylated ACV, which terminates DNA chain elongation and can trap RT at the site of termination. Consequently, ACV suppresses HIV-1 in HHV-coinfected human tissues but not in a HHV-free tissue or cell lines. However, addition of HHV-6-infected cells or administration of ACV monophosphorylated prodrugs (not requiring activation by HHV-kinases) renders HIV sensitive to ACV in these cells.
These data suggest that ACV is active against HIV-1 in tissues coinfected with various HHVs, provide new insights in ACV activity into HIV/HSV-2-coinfected patients, and provide strategies for the development of new HIV-1 RT inhibitors.